Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Minority Interest (2020 - 2025)

Historic Minority Interest for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to $96000.0.

  • Barinthus Biotherapeutics' Minority Interest fell 4251.5% to $96000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $96000.0, marking a year-over-year decrease of 4251.5%. This contributed to the annual value of $106000.0 for FY2024, which is 4976.3% down from last year.
  • Barinthus Biotherapeutics' Minority Interest amounted to $96000.0 in Q3 2025, which was down 4251.5% from $104000.0 recorded in Q2 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Minority Interest peaked at $518000.0 during Q2 2021, and registered a low of $96000.0 during Q3 2025.
  • Its 5-year average for Minority Interest is $261842.1, with a median of $253000.0 in 2023.
  • Its Minority Interest has fluctuated over the past 5 years, first surged by 4440.43% in 2022, then tumbled by 4976.3% in 2024.
  • Quarter analysis of 5 years shows Barinthus Biotherapeutics' Minority Interest stood at $437000.0 in 2021, then crashed by 30.21% to $305000.0 in 2022, then plummeted by 30.82% to $211000.0 in 2023, then plummeted by 49.76% to $106000.0 in 2024, then fell by 9.43% to $96000.0 in 2025.
  • Its Minority Interest was $96000.0 in Q3 2025, compared to $104000.0 in Q2 2025 and $99000.0 in Q1 2025.